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Accepted 25 October 2017; Published online 31 October 2017AbstractObjectives: We compared characteristics and outcomes of children enrolled in a randomized controlled trial (RCT) comparing oral
amoxicillin and benzyl penicillin for the treatment of chest indrawing pneumonia vs. children who received routine care to determine
the external validity of the trial results.
Study Design and Setting: A retrospective cohort study was conducted among children aged 2-59 months admitted in six Kenyan hos-
pitals. Data for nontrial participants were extracted from inpatient records upon conclusion of the RCT. Mortality among trial vs. nontrial
participants was compared in multivariate models.
Results: A total of 1,709 children were included, of whom 527 were enrolled in the RCT and 1,182 received routine care. History of a
wheeze was more common among trial participants (35.4% vs. 11.2%; P ! 0.01), while dehydration was more common among nontrial
participants (8.6% vs. 5.9%; P 5 0.05). Other patient characteristics were balanced between the two groups. Among those with available
outcome data, 14/1,140 (1.2%) nontrial participants died compared to 4/527 (0.8%) enrolled in the trial (adjusted odds ratio, 0.7; 95%
confidence interval: 0.2e2.1).
Conclusion: Patient characteristics were similar, and mortality was low among trial and nontrial participants. These findings support
the revised World Health Organization treatment recommendations for chest indrawing pneumonia.  2017 The Authors. Published by
Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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In the hierarchy of sources of evidence for guideline
development, randomized controlled trials (RCTs) are gener-
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4.0/).RCTs, however, argue that the strict enrollment criteria and
enhanced care provided to patients enrolled in clinical trials
limit the external validity of the findings to routine clinical
settings [2]. A ‘‘trial effect’’ demonstrating better overall
outcomes among patients recruited in clinical trials, indepen-
dent of the effectiveness of the intervention treatment, has
previously been described [3]. This effect is arguably more
pronounced in resource limited settings where routine care
is often considerably poorer than care provided to partici-
pants of clinical trials assigned to receive ‘‘standard care.’’
In a large pragmatic trial on fluid resuscitation among febrile
children in sub-Saharan Africa, mortality among control
subjects was noted to have been 50% lower than that
observed in routine practice before the trial [4].
For childhood pneumonia, the leading single cause of
childhood mortality, data from large clinical trials conduct-
ed in predominantly Asian populations were used to inform
a major revision of the World Health Organization (WHO)s article under the CC BY license (http://creativecommons.org/licenses/by/
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Key findings
 In this study of hospitalized children with chest in-
drawing pneumonia, routinely collected observa-
tional data from nontrial patients provide
estimates of clinical characteristics and mortality
comparable to those of trial participants.
What this adds to what was known?
 Effectiveness of oral amoxicillin for the treatment
of chest indrawing pneumonia has been demon-
strated in clinical trials.
 The results of this analysis suggest generalizability
of clinical trial data to routine settings where pneu-
monia mortality is perceived to be high.
What is the implication and what should change
now?
 The findings lend support to the WHO revised rec-
ommendations and provide useful evidence for na-
tional programs implementing pneumonia case
management in sub-Saharan Africa where uptake
of the WHO guidelines has been poor.
2 A. Agweyu et al. / Journal of Crecommendations for empirical therapy. In the revised
recommendations, children with indrawing pneumonia
(lower chest indrawing in the absence of danger signs sug-
gestive of more severe forms of disease) are to be managed
as outpatients with oral amoxicillin in place of the previous
guidelines requiring inpatient therapy with injectable
penicillin [5]. Uptake of this policy has been poor across
sub-Saharan Africa partly due to fears of the safety of home
management of a population of children with a potentially
high risk of mortality [6]. These concerns are partially
addressed in a pragmatic noninferiority RCT of oral amox-
icillin vs. benzyl penicillin conducted at six Kenyan hospi-
tals [7]. In a parallel exercise, we collected observational
data from patients who were treated for pneumonia at the
participating hospitals while the trial was recruiting, but
who did not take part in the trial. Reasons for not partici-
pating in the trial included refusal to provide consent or
failure of the recruiting clinician to enroll the patient in
the trial because they were admitted at night or during
weekends when recruitment was suspended. Variations of
this design have been previously applied in a limited num-
ber of studies conducted in high-income settings [8,9].
We specifically sought to compare mortality among
children enrolled in the RCT with a similar population of
nontrial participants hospitalized at the same health facil-
ities over the period the trial was conducted to addressanticipated concerns from clinicians and policymakers
regarding the generalizability of the trial results.2. Methodology
2.1. Participants
We created a retrospective cohort of children admitted
with chest indrawing pneumonia (WHO 2014 definition)
at six Kenyan public hospitals. The primary independent
variable was enrollment vs. nonenrollment in a RCT
comparing the effectiveness of oral amoxicillin vs. benzyl
penicillin for chest indrawing pneumonia [7]. The main
outcome was mortality during the inpatient period. The
study sites were average-sized hospitals with
2,500e4,500 pediatric admissions each year. Three of the
facilities were located in malaria endemic regions of the
country. Four of the sites were district-level hospitals, while
two were provincial referral hospitals. All six hospitals
were medical internship training centers with inpatient pe-
diatric departments headed by at least one pediatrician.2.2. Eligibility criteria
We included children aged between 2 and 59 months
hospitalized with pneumonia at the study sites between
September 2011 and August 2013. To overcome the potential
effects of alternative antibiotic treatments on clinical outcome
and the challenge of accurate identification of ineligible chil-
dren with undocumented exclusion criteria, we restricted the
study population to children with chest indrawing at admis-
sion who were treated with either benzyl penicillin alone at
50,000 IU/kg every 6 hours (observational study and control
group of RCT) or oral amoxicillin at 40e45 mg/kg every
12 hours (intervention group of the RCT). Children with
documented clinical diagnoses that would preclude the use
of benzyl penicillin or amoxicillin monotherapy including se-
vere acute malnutrition, HIV, meningitis, and WHO-defined
very severe pneumonia were excluded. Caregivers who
declined to provide written informed consent for enrollment
were excluded from the clinical trial but were considered
for inclusion in the observational cohort.2.3. Sample size
A total of 527 children were enrolled in the clinical trial.
Assuming a similar number of eligible participants were
admitted at the study hospitals but not enrolled in the clin-
ical trial, a sample size of 1,054 would provide 80% power
to detect a twofold higher mortality among children who
were not enrolled in the trial vs. those enrolled in the trial
at a 5% significance level assuming an estimated mortality
risk of 1% among children enrolled in the clinical trial
based the results of a similar large multicountry clinical
trial [10].
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Clinical documentation for the observational cohort was
not monitored as rigorously as it was in the clinical trial.
However, considerable effort was made to ensure overall
quality of clinical care and documentation through training
for clinical staff on the pneumonia guidelines at the begin-
ning of the study and at 3e6 monthly intervals, promotion
of the use of structured patient admission forms during
clinical assessment, and provision of the national pediatric
guidelines to health workers. Staff also underwent a 5-day
course designed for the dissemination of the Ministry of
Health pediatric guidelines for health facilities called
Emergency Triage Assessment and Treatment Plus [11] at
various times during the study period.
Children participating in the RCT were enrolled prospec-
tively by a trained study clinician after screening for
eligibility including provision of written informed consent
from caregivers. All trial participants were reviewed daily
by the study clinician in consultation with a pediatrician based
at the hospital. The trial protocol outlined specific criteria
defining treatment failure among trial participants to which
the clinical team were advised to adhere. The procedures
specific to the clinical trial is described separately [7].
Data were entered daily in an online database that was
reviewed by the trial principal investigator and study
pediatrician for conflicting or missing observations which
were communicated directly to the site clinician for prompt
correction.
Trained research assistants extracted data for the nontrial
participants retrospectively from hospital records. Supervi-
sion of the data abstraction exercise was provided onsite by
the hospital pediatrician and a trained clinical officer with
additional telephone and e-mail support from the study
principal investigator.
The primary data collection tool was developed in
REDCap, an open source web-based database application
[12]. The structure of the database was based on the Ministry
of Health’s Pediatric Admission Record form [11] that
captures data on patient sociodemographic and clinical
characteristics, and admission diagnosis. Additional fields
were included to record data on daily inpatient care
including treatment prescribed and information on discharge
diagnosis and clinical outcome (survival or death).
2.5. Statistical analysis
Data were inspected for distribution and completeness.
Characteristics of the study population were summarized
and compared by trial status (trial vs. nontrial participants).
The univariate odds ratio for mortality between trial and
nontrial participants was reported with an accompanying
95% confidence interval (CI). Potential causal pathways
relating enrollment in the clinical trial, patient characteris-
tics, and mortality were developed to determine variables
that would be considered potential confounders. Variables
that altered the strength of the primary association inbivariate analyses were selected for inclusion in the multi-
variate models along with age and hospital level which
were regarded as a priori covariates. To account for missing
data on variables selected for inclusion in the multivariable
model, multiple imputation by chained equations was
performed under a missing at random assumption. This
method was favored for its flexibility in handling both
categorical and continuous variables [13,14]. To enhance
efficiency of the imputation model, we included variables
for which documentation was complete or almost complete.3. Results
Medical records were available for 1,709 children aged
2e59 months hospitalized at the study sites between
September 2011 and August 2013, with pneumonia and
treated with penicillin or amoxicillin monotherapy. Of these
children, 527 (30.8%) were enrolled in the clinical trial and
1,182 (69.2%) received routine care. Two-thirds of the
children (1,242/1,709) studied were hospitalized at the four
district hospitals. Study participants in both groups had a
median age of 13 months [interquartile range (IQR):
7e24 months] and duration of symptoms of 3 days (IQR:
2e4 days). Sex, immunization status, duration of symptoms,
nutritional status, and the presence of pallor were compara-
ble between the two groups (Table 1). In contrast, history of
a wheeze was reported three times more frequently among
children enrolled in the clinical trial (35.4% vs. 11.2%;
P! 0.01); dehydration was more common among children
in the observational cohort (8.6%) than those in the clinical
trial (5.9%), P 5 0.05; and the proportion of children
enrolled from district hospitals was greater among nontrial
(75.0%) vs. trial (67.4%) participants (P! 0.01). More than
90% of the children for whom information on immunization
status was available were reported to have received the
routine childhood vaccines, including the pneumococcal
conjugate vaccine, according to the national immunization
schedule. Data on patient characteristics and outcome were
documented completely for all the clinical trial participants.
Among children in the observational cohort, data were
missing on immunization status (10.0%), weight for age Z
score (10.7%), history of a wheeze (45.0%), assessment
for pallor (10.9%), and survival/death (3.6%).3.1. Univariate associations for mortality
Mortality among nontrial participants for whom
outcome data were complete was 14/1,140 (1.2%) vs. 4/
527 (0.8%) for those enrolled in the trial [unadjusted odds
ratio (OR), 0.6; 95% CI: 0.2e1.9]. Children aged
2e11 months were more than four times more likely to
die than those aged 12e59 months (OR, 4.5; 95% CI:
1.5e13.7). More deaths were also observed among children
who reported a duration of symptoms of 3 or more days
compared to children with shorter durations of illness
Table 1. Baseline characteristics of study participants
Patient characteristic
Observational cohort Clinical trial cohort
P-valueFrequency (%)/median (IQR) N Frequency (%)/median (IQR) N
Age 12e59 mo 654 (55.3) 1,182 292 (55.4) 527 0.90
Age 2e11 mo 528 (44.7) 235 (44.6)
Female 479 (41.0) 1,182 226 (42.9) 527 0.46
Male 703 (59.0) 301 (57.1)
Immunization up to date 994 (93.4) 1,064 501 (95.1) 527 0.20
Immunization not up to date 70 (6.6) 26 (4.9)
Duration of symptoms (days) 3 (2, 4) 1,182 3 (2, 4) 527 0.15
Weight-for-age Z score 2SD 917 (86.9) 1,055 447 (84.8) 527 0.25
Weight for Age Z score !2SDa 138 (13.1) 80 (15.2)
No history of wheeze 577 (88.8) 650 340 (64.6) 527 !0.01
History of wheeze 73 (11.2) 187 (35.4)
Pallor absent 1,004 (95.3) 1,053 498 (94.5) 527 0.46
Pallor present 49 (4.7) 29 (5.5)
Dehydration absent 1,080 (91.4) 1,182 496 (94.1) 527 0.05
Dehydration present 102 (8.6) 31 (5.9)
District hospitalb 887 (75.0) 1,182 355 (67.4) 527 !0.01
Provincial hospital 295 (25.0) 172 (32.6)
a Weight for age Z score classification based on World Health Organization Child Growth Standards.
b Vs. provincial hospital.
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at provincial-level facilities (OR, 2.7; 95% CI: 1.1e6.8).
There was weak evidence that up-to-date immunization
status was associated with reduced odds of death (OR,
0.3; 95% CI: 0.1e1.1). Mortality did not vary by sex, the
presence of moderate malnutrition, history of a wheeze,
nor the presence of pallor (Table 2).
In bivariate analyses, the association between participa-
tion in the trial and mortality was modestly altered after
adjusting for age group, malnutrition, history of a wheeze,
pallor, and dehydration. There was no statistical interaction
by any of the variables examined for the primary associa-
tion (Table 3).
3.2. Multivariate associations for mortality
Associations for mortality among trial vs. nontrial
patients were further examined in a multiple imputation
model adjusting for age group, hospital level of care,
malnutrition, history of a wheeze, pallor, and dehydration.
The result was similar to that obtained in the univariate
analyses (adjusted OR, 0.7; 95% CI: 0.2e2.1). Over the
whole sample (trial and observational cohort), children
aged 2e11 months had a fourfold increased odds of death
compared to those aged 12e59 months. Duration of
symptoms and hospital level of care were, however, not
independently associated with mortality (Table 4).4. Discussion
In this comparative study of children hospitalized with
pneumonia enrolled in a clinical trial vs. those who
received routine care, overall mortality was low and similar
in both groups. Our findings are consistent with the resultsof previously conducted clinical trials that informed a
major recent revision in the WHO guidelines for the man-
agement of childhood pneumonia recommending outpatient
therapy for children with lower chest wall indrawing with
oral amoxicillin. The low mortality, however, contrasts with
the results of previous observational studies conducted in
sub-Saharan Africa prior to the introduction of the pneumo-
coccal vaccine in which mortality was more than three
times higher [15,16]. This difference may be partly
attributed to the wide immunization coverage against the
major causes of bacterial pneumonia, resulting in a relative
increase in the proportion of children presenting with
self-limiting viral pneumonia [17]. Unfortunately, the
etiology of pneumonia in low-income settings in the era
postintroduction of the Haemophilus influenzae type B
and pneumococcal conjugate vaccines remains poorly
understood [17,18] and was not examined in our study.
Most baseline characteristics were evenly distributed
between the two groups. The disproportionately larger
number of children in the trial with history of a wheeze, a
symptom associated with viral bronchiolitis and reduced risk
of death among young children with pneumonia [19], may
suggest biased recruitment of patients who were perceived
to be less sick in this group. However, the apparent
difference may also be due to inadequate assessment for
the presence of this symptom among nontrial participants
(documentation on history of a wheeze was missing for
almost half of nontrial participants). To mitigate measure-
ment error arising from missing data, we used multiple
imputation to generate the final estimates of effect. Since
data for the children included in the observational cohort
were collected retrospectively, it was not possible to ascer-
tain the characteristics of this subpopulation in detail. Thus,
the presence of underlying malnutrition, HIV infection, and
Table 2. Univariate risk factors for mortality among study participants
Patient characteristic Number of deaths/N % Mortality Odds ratio (95% CI) P-value
Observational cohort 14/1,140 1.2 1.0
Clinical trial cohort 4/527 0.8 0.6 (0.2, 1.9) 0.40
Age 12e59 mo 4/927 0.4 1.0
Age 2e11 mo 14/740 1.9 4.5 (1.5, 13.7) 0.004
Female 8/692 1.2 1.0
Male 10/964 1.0 0.9 (0.4, 2.3) 0.8
Immunization not up to date 3/92 3.3 1.0
Immunization up to date 15/1,434 1.1 0.3 (0.1, 1.1) 0.06
Duration of symptoms ! 3 days 10/1,174 0.4 1.0
Duration of symptoms 3 days 8/493 1.6 4.0 (1.2, 13.9) 0.02
Weight-for-age Z score 2SD 11/1,334 0.8 1.0
Weight-for-age Z score !2SD 4/212 1.9 2.3 (0.7, 7.3) 0.14
No history of wheeze 11/899 1.2 1.0
History of wheeze 1/259 0.4 0.3 (0.0, 2.4) 0.24
Pallor absent 14/1,471 1.0 1.0
Pallor present 2/71 2.8 3.0 (0.7, 13.6) 0.13
Dehydration absent 16/1,537 1.0 1.0
Dehydration present 2/130 1.5 1.5 (0.3, 6.5) 0.60
District hospital 9/1,184 0.8 1.0
Provincial hospital 9/451 2.0 2.7 (1.1, 6.8) 0.03
Abbreviation: CI, confidence interval.
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mented by the admitted clinician could not be accounted
for among the nontrial participants. While these factors
suggest dissimilarity between the two groups, the compari-
son conducted in this study provides an important picture
of outcomes among these children in real lifeda more
relevant consideration for policymakers interested in
understanding the risk of death within this population.
Out of the large number of published pragmatic trials,
very few attempts to demonstrate the extent to which the
populations studied compare to real patients to whom
the findings ultimately apply. Indeed, trials designed withTable 3. Stratified and Mantel-Haenszel adjusted odds ratios for the associa
Patient characteristic
Stratum specific odds
ratio (95% CI)
Observational cohort 14/1,140
Clinical trial cohort 4/527
Age 12e59 mo 0.0 (e)
Age 2e11 mo 0.9 (0.3, 3.0)
Female 1.2 (0.3, 5.2)
Male 0.2 (0.0, 1.9)
Immunization not up to date 0.0 (e)
Immunization up to date 0.7 (0.2, 2.3)
Duration of symptoms ! 3 days 0.0 (e)
Duration of symptoms 3 days 0.7 (0.2, 2.3)
Weight-for-age Z score 2SD 0.5 (0.1, 2.2)
Weight-for-age Z score !2SD 1.7 (0.2, 12.3)
No history of wheeze 0.6 (0.2, 2.5)
History of wheeze 0.0 (e)
Pallor absent 0.8 (0.3, 2.7)
Pallor present 0.0 (e)
Dehydration absent 0.5 (0.1, 1.8)
Dehydration present 3.3 (0.2, 54.9)
District hospital 1.3 (0.3, 5.1)
Provincial hospital 0.2 (0.0, 1.8)
Abbreviation: CI, confidence interval.the intention of generating evidence to be used in ‘‘real-
world’’ settings have been criticized for being more explan-
atory than initially intended, limiting their utility for
decision-making [20]. The emergence of tools to aid
trialists in designing studies that appropriately match their
intended purposes is likely to improve the quality of both
explanatory and pragmatic trials [21,22]. The possibility
of selection bias can never be completely excluded in a
study comparing RCT with observational evidence as
pointed out above. Certainly, if results differ, the possibility
that one group had worse prognosis than the other cannot
be excluded. Nor, if they are similar across the trial andtion between trial enrolment and mortality
M-H summary odds
ratio (95% CI)
P-value
chi-square test
P-value test
for interaction
0.40
0.7 (0.2, 2.0) 0.46 0.22
0.6 (0.2, 1.9) 0.38 0.18
0.6 (0.2, 1.9) 0.38 0.37
0.6 (0.2, 1.9) 0.38 0.37
0.7 (0.2, 2.3) 0.58 0.31
0.8 (0.2, 2.7) 0.66 0.44
0.7 (0.2, 2.1) 0.48 0.32
0.7 (0.2, 2.0) 0.47 0.20
0.6 (0.2, 1.8) 0.38 0.15
Table 4. Independent risk factors for mortality among study
participants
Patient characteristic
Adjusted odds
ratioa (95% CI) P-value
Observational cohort 1.0
Clinical trial cohort 0.7 (0.2, 2.1) 0.51
Age 12e59 mo 1.0
Age 2e11 mo 4.0 (1.3, 12.5) 0.02
Weight-for-age Z score 2SD 1.0
Weight-for-age Z score !2SD 2.0 (0.6, 6.7) 0.26
Pallor absent 1.0
Pallor present 3.3 (0.6, 16.8) 0.15
No history of wheeze 1.0
History of wheeze 0.4 (0.1, 2.7) 0.33
Dehydration absent 1.0
Dehydration present 1.1 (0.2, 4.8) 0.93
District hospital 1.0
Provincial hospital 2.2 (0.8, 5.6) 0.11
Abbreviation: CI, confidence interval.
a Multivariate model adjusted for trial versus nodtrial status. age,
weight for age Z score, pallor, history of wheeze, clinical hydration sta-
tus, and level of care of health facility.
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assume that a true difference has not been obscured. That
said, the similarity in both the absolute and relative differ-
ences across trial and nontrial groups, in both the adjusted
and unadjusted results, does suggest that a measure of
reassurance might be derived that the trial result is general-
izable in this particular case.
A major limitation of this study was its retrospective
design and reliance on routine clinical data. Missing data
were encountered across several variables including clinical
outcome. Although it is not possible to ascertain the true
values of the missing observations, we used multiple impu-
tation to overcome potential bias arising from exclusion of
patients with missing data. The results of this analysis were
similar to those of the univariate analysis excluding
children with missing outcome data.5. Conclusions
Routinely collected observational data, when used to
complement the findings of clinical trials, offer a valuable
and low-cost opportunity for addressing the weaknesses
inherent to traditional RCTs [23,24]. The validity of this
approach is, however, dependent on the completeness and
quality of clinical documentation which is currently a ma-
jor challenge in settings where resources are deficient
[25,26]. Nontrial participants had similar characteristics
to those recruited in the RCT. The risk of mortality in
routine care settings was comparable to that reported in
clinical trials, among children who are currently proposed
to receive outpatient therapy under the revised WHO
guidelines. The findings add to existing evidence to further
inform ongoing discussions on case management for child-
hood pneumonia in sub-Saharan Africa.Acknowledgments
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